Results 221 to 230 of about 33,379 (274)
Some of the next articles are maybe not open access.
Expert Opinion on Emerging Drugs, 2005
Systemic and superficial fungal infections have progressively emerged over the past few decades as an increasing cause of human disease, especially in the immunocompromised host. Control of fungal disease has proved difficult because few risk factors are potentially preventable; the population at highest risk for fungal disease, the immunocompromised ...
Anne, Chen, Jack D, Sobel
openaire +2 more sources
Systemic and superficial fungal infections have progressively emerged over the past few decades as an increasing cause of human disease, especially in the immunocompromised host. Control of fungal disease has proved difficult because few risk factors are potentially preventable; the population at highest risk for fungal disease, the immunocompromised ...
Anne, Chen, Jack D, Sobel
openaire +2 more sources
2000
Abstract Systemic administration is accompanied by headache and somnolence in 10% of cases. Acute toxic psychosis with confusion, hallucinations, and delusions is rarely described with each agent (1,2). Intrathecal administration is associ ated with arachnoiditis, without ischemic myelopathy (3). The azole antifungal
openaire +1 more source
Abstract Systemic administration is accompanied by headache and somnolence in 10% of cases. Acute toxic psychosis with confusion, hallucinations, and delusions is rarely described with each agent (1,2). Intrathecal administration is associ ated with arachnoiditis, without ischemic myelopathy (3). The azole antifungal
openaire +1 more source
Clinical Infectious Diseases, 1992
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +2 more sources
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +2 more sources
Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain
Clinical Microbiology and Infection, 2021Patricia Carmen Muñoz García +2 more
exaly